TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32772049
Drug: Personalized medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized medicine based on human genetics for cardiovascular diseases
Study: 34724045
Drug: Crystalloid administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crystalloid administration
Study: 35521789
Drug: Glucagon (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucagon (1 mg s.c. injection)
Study: 35521789
Drug: Copeptin cut-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copeptin cut-off level of 4.6 pmol/L
Study: 39555827
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment targeting systolic blood pressure <120 mm Hg
Study: 39555827
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment targeting systolic blood pressure <140 mm Hg
Study: 36308110
Drug: Intracameral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral lidocaine hydrochloride 1% and tropicamide injection 0.02%
Study: 34714539
Drug: Group II
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group II (0.3 mL/kg of 0.25 percent bupivacaine, fentanyl 50 µg, and naloxone 100 ng)
Study: 34714539
Drug: Group I
Normalized name: Platelet group IIa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group I (0.3 mL/kg of 0.25 percent bupivacaine)
Study: 34714539
Drug: Group III
Normalized name: Corticosteroids, potent (group III)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group III (0.3 mL/kg of 0.25 percent bupivacaine and fentanyl 50 µg)
Study: 36175722
Drug: Biologic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic therapy prior to surgery
Study: 36175722
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no biologic therapy)
Study: 34137476
Drug: Dipyridamole (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (up to 300 mg)
Study: 36244879
Drug: Standard-dose influenza
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose influenza vaccine (SD)
Study: 33769732
Drug: Methotrexate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (0.3 mg/kg/week)
Study: 33769732
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Methotrexate (0.15 mg/kg/week) and Cyclosporine (2.5 mg/kg/day)
Study: 37449426
Drug: Automated Insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Automated Insulin Delivery (AID)
Study: 34756489
Drug: Kinesio taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kinesio taping (KT) on extensor carpi radialis brevis and longus (ECRB/L)
Study: 34756489
Drug: Placebo taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo taping (PT) on extensor carpi radialis brevis and longus (ECRB/L)
Study: 35807160
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% fluorometholone combined with 0.05% azelastine
Study: 35807160
Drug: Topical 0.1%
Normalized name: adapalene topical 0.1% topical gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.1% fluorometholone alone
Study: 35807160
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (combination and isolated fluorometholone)
Study: 33774558
Drug: Internet-delivered exposure
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered exposure therapy
Study: 33774558
Drug: Internet-delivered cognitive
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered cognitive behavioral therapy (iCBT)
Study: 35218019
Drug: Targeted temperature
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted temperature treatment (TTM) at 33°C for 24 or 48 hours
Study: 34988932
Drug: NeuroMuscular Taping
Approvals — FDA: no, EMA: no, PMDA: no
Description: NeuroMuscular Taping (NMT) applied over 8 days following back-school therapy (BST)
Study: 34988932
Drug: Back-school therapy
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back-school therapy (BST) alone
Study: 34507361
Drug: Gonyautoxin 2/3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonyautoxin 2/3 (GTX 2/3) 40 ?g in 30 mL sodium chloride 0.9%
Study: 34507361
Drug: Levobupivacaine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levobupivacaine (300 mg), ketorolac (60 mg), and epinephrine (1 mg) in 150 mL sodium chloride 0.9%
Study: 35968286
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Mecobalamin tablets)
Study: 34496751
Drug: Education based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education based on Acceptance and Commitment Therapy (ACT)
Study: 35233984
Drug: Goserelin (Z),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goserelin (Z), 3.6 mg, n = 8
Study: 33176437
Drug: Omecamtiv Mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv Mecarbil (OM) 25 mg BID
Study: 33176437
Drug: Omecamtiv Mecarbil
Normalized name: omecamtiv mecarbil
DrugBank: Omecamtiv Mecarbil (DB11816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omecamtiv Mecarbil (OM) pharmacokinetically guided dose titration (OM-PK)
Study: 34606293
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene system (test group) involving a novel smart‐connected Oral‐B® iO oscillating‐rotating electric toothbrush, 0.454 percent stabilized stannous fluoride dentifrice, 0.07 percent cetylpyridinium chloride rinse, and floss
Study: 32806525
Drug: Face-to-face exercise
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face exercise performed by an instructor (Group L)
Study: 34282647
Drug: 3-minute dilute
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-minute dilute povidone-iodine soak and scrub followed by standard 2-step skin preparation (alcohol scrub and chlorhexidine/alcohol paint)
Study: 34282647
Drug: Standard 2-step
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 2-step skin antiseptic preparation (alcohol scrub followed by chlorhexidine/alcohol paint)
Study: 32985369
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of 15 mg/kg TXA
Study: 34000245
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with concurrent temozolomide (75 mg/m2 per day)
Study: 34000245
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with adjuvant temozolomide (12 4-week cycles of 150-200 mg/m2 on days 1-5)
Study: 35584872
Drug: Oral semaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral semaglutide for 24 weeks
Study: 33060078
Drug: Stand-alone VR
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone VR (6-week internet-based intervention with weekly online sessions and daily exercises)
Study: 35383253
Drug: Solacea 19H
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solacea 19H dialyzer with 1/4th of the regular anticoagulation dose
Study: 34058910
Drug: Laryngoplasty or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laryngoplasty or voice therapy
Study: 34058910
Drug: Voice therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice therapy alone
Study: 34010180
Drug: Increasing WBCc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing WBCc tertiles (mean 5.6, 7.5, and 10.1 × 10^9/L)
Study: 32526017
Drug: tDCS +
Approvals — FDA: no, EMA: no, PMDA: no
Description: tDCS + exercise therapies
Study: 32526017
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS + exercise therapies
Study: 36457045
Drug: digital cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: digital cognitive-behavioral therapy for insomnia (dCBT-I)
Study: 36457045
Drug: clinician-led cognitive-behavioral
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: clinician-led cognitive-behavioral therapy for insomnia (CBT-I)
Study: 36261277
Drug: 2-week interruption
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2-week interruption in methotrexate treatment
Study: 36261277
Drug: Continued methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continued methotrexate treatment
Study: 34554692
Drug: Selenium 200
Normalized name: SELENIUM 200MCG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium 200 µg
Study: 35452086
Drug: Capecitabine maintenance
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine maintenance therapy using lower dosage and higher frequency
Study: 33303575
Drug: Anti-PD1 immunotherapy
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Anti-PD1 immunotherapy
Study: 33303575
Drug: Small-molecule inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small-molecule inhibitor targeting HO-1
Study: 33009852
Drug: Take 5
Normalized name: Chaga Mushroom Mycelium/Cholecalciferol/Cordyceps/Maitake/Reishi/Shiitake 50 MG-3.75 MCG-50 MG-50 MG-50 MG-50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 5 Minutes treatment (5 to 10 minutes of dedicated communication with parents)
Study: 33009852
Drug: Take 5
Normalized name: Chaga Mushroom Mycelium/Cholecalciferol/Cordyceps/Maitake/Reishi/Shiitake 50 MG-3.75 MCG-50 MG-50 MG-50 MG-50 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Take 5 Minutes treatment
Study: 34819017
Drug: Monthly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly fremanezumab (225 mg)
Study: 34246226
Drug: Quarterly fremanezumab
Normalized name: Fremanezumab
DrugBank: Fremanezumab (DB14041)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Quarterly fremanezumab (225 mg)
Study: 32880602
Drug: Eribulin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin plus Pembrolizumab (Eribulin 1.4 mg/m2 IV on days 1 and 8 plus Pembrolizumab 200 mg/m2 IV on day 1 of a 21-day cycle)
Study: 32880602
Drug: Crossover treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover treatment with Pembrolizumab after progression on Eribulin monotherapy
Study: 32783267
Drug: 0.7% fumaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% fumaric acid treatment on fiber post surface and 0.7% fumaric acid treatment on dentin surface
Study: 32783267
Drug: 9% hydrofluoric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 9% hydrofluoric acid treatment on fiber post surface and 0.7% fumaric acid treatment on dentin surface
Study: 32783267
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no conditioning) on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Study: 32783267
Drug: 17% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17% EDTA treatment on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Study: 32783267
Drug: 0.7% fumaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7% fumaric acid treatment on dentin surface and 9% hydrofluoric acid treatment on fiber post surface
Study: 34182194
Drug: OT+XNJ (i.v.
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT+XNJ (i.v. 20 ml/daily)
Study: 34182194
Drug: OT+low dose-YB
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: OT+low dose-YB (oral, 1,000 mg/day)
Study: 34182194
Drug: OT+high dose-YB
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: OT+high dose-YB (oral, 2,000 mg/day)
Study: 34182194
Drug: XNJ, l-YB,
Approvals — FDA: no, EMA: no, PMDA: no
Description: XNJ, l-YB, h-YB
Study: 33972573
Drug: PT150 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: PT150 (900 mg/day) administered orally for five days
Study: 32156255
Drug: Personalized dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized dosage of MPH
Study: 32156255
Drug: MPH over
Normalized name: MPH
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MPH over treatment period
Study: 33305631
Drug: OLNP-06, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLNP-06, 200 mg twice daily
Study: 33305631
Drug: Placebo, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, 200 mg twice daily
Study: 32701529
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of TXA
Study: 33260939
Drug: Recommended behavior
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recommended behavior group (RB group) - drank 200 mL of water every 2 h
Study: 33260939
Drug: Half amount
Normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half amount group (HA group) - drank 100 mL of water every 2 h
Study: 33260939
Drug: High frequency
Normalized name: ALCOHOL 0.7 mL in 1 mL TOPICAL SOLUTION [enMotion Foam High Frequency Use]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High frequency group (HF group) - drank 110 mL of water every 1 h
Study: 36268614
Drug: Home-based Intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based Intensive Nutrition Therapy (HINT)
Study: 36268614
Drug: Standard Medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard Medical Therapy (SMT)
Study: 32856209
Drug: Methylprednisolone 16
Normalized name: methylprednisolone 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 16 mg twice daily for 7 days
Study: 33980184
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 0.08 mg/kg oxycodone immediately after completion of the surgical procedure
Study: 33980184
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline injection (Control group)
Study: 35184297
Drug: CDX-0159 (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDX-0159 (0.3, 1, 3, and 9 mg/kg)
Study: 36302893
Drug: HTI vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTI vaccines (DNA.HTI, MVA.HTI, ChAdOx1.HTI)
Study: 36302893
Drug: HTI vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HTI vaccines
Study: 34336620
Drug: Extracorporeal Shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal Shock Wave Therapy (ECSWT) - three sessions, once a week for three weeks
Study: 34336620
Drug: Phonophoresis therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phonophoresis therapy - ultrasound using hydrocortisone gel 1% over the trigger point, three times a week for three weeks
Study: 33909860
Drug: Non-fluoridated gel
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fluoridated gel (control)
Study: 32483058
Drug: Hypnotic cognitive
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic cognitive therapy
Study: 32483058
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive therapy
Study: 36129032
Drug: Alteplase at
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alteplase at 0.6 mg/kg
Study: 34969619
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (nonverbal and instrumental music in the forms of taqsim, saz semai, and peshrev at speeds of 60 and 100)
Study: 32316938
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate 300 mg
Study: 35141971
Drug: Voice treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice treatment (n = 6)
Study: 35141971
Drug: Articulation treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Articulation treatment (n = 7)
Study: 35141971
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (n = 6)
Study: 33197668
Drug: Six weeks
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six weeks of twice‐weekly Swedish Massage Therapy (SMT)
Study: 33197668
Drug: Additional six
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional six weeks of twice‐weekly Swedish Massage Therapy (SMT)
Study: 35813441
Drug: Comprehensive care
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive care based on appropriate Chinese medicine techniques
Study: 34077684
Drug: Ca‐D‐fortified yogurt
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ca‐D‐fortified yogurt drink (CDY; 1000 IU vitamin D plus 500 mg calcium)
Study: 34389250
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of ethambutol (12.5 mg/kg/d)
Study: 34389250
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of ethambutol (15.4 mg/kg/d)
Study: 34389250
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of ethambutol
Study: 34389250
Drug: Lower dose
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower dose of ethambutol
Study: 34389250
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of ethambutol
Study: 34423904
Drug: Rapastinel 900
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel 900 mg
Study: 34423904
Drug: Rapastinel 1800
Normalized name: Rapastinel
DrugBank: Rapastinel (DB11801)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapastinel 1800 mg
Study: 34423904
Drug: Alprazolam 0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.75 mg (positive control)
Study: 34423904
Drug: Ketamine 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 0.5 mg/kg (clinical comparator)
Study: 32664290
Drug: Rice and
Normalized name: Rice
DrugBank: Rice (DB10563)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rice and pea combination (RP, n = 6)
Study: 36040184
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral electrolyte-carbohydrate nutrition supplement (OECNS)
Study: 36040184
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (meal nutrition supplements and water)
Study: 33885704
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) starting dose of 50 Gy in 5 fractions (central lung, mediastinal/cervical lymph node), 45 Gy in 3 fractions (peripheral lung, abdominal-pelvic, liver), and 30 Gy in 3 fractions (bone/osseous, spinal/paraspinal)
Study: 32072763
Drug: LIK066 (licogliflozin)
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 (licogliflozin) 2.5 mg once daily
Study: 32072763
Drug: LIK066 (licogliflozin)
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 (licogliflozin) 10 mg once daily
Study: 32072763
Drug: LIK066 (licogliflozin)
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 (licogliflozin) 25 mg once daily
Study: 32072763
Drug: LIK066 (licogliflozin)
Normalized name: Licogliflozin
DrugBank: Licogliflozin (DB15048)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 (licogliflozin) 50 mg once daily
Study: 33237242
Drug: Multilink Speed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilink Speed (ML)
Study: 35695053
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulin (IVIG) at a dose of 5 g/day for 3 days (total 15 g or 0.3 g/kg)
Study: 35695053
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulin (IVIG)
Study: 34474583
Drug: Rivaroxaban or
Normalized name: rivaroxaban Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban or rivaroxaban plus an antiplatelet agent
Study: 34961782
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 8 mg
Study: 34961782
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 8 mg + Etodolac (ETO)
Study: 34961782
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 8 mg + Ketorolac (KET)
Study: 34961782
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 8 mg + Ibuprofen (IBU)
Study: 34961782
Drug: Dexamethasone (DEX)
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone (DEX) 8 mg + Loxoprofen (LOX)
Study: 34961782
Drug: Paracetamol 750
Normalized name: Hydrocodone bitartrate 7.5 mg and paracetamol 750 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 750 mg (rescue analgesics)